TradFi is betting on an altcoin season in Q4AI is a macro trend that's not going awayHere's the roundup of the latest DeAI news to get you up to speed🧵(1/14) https://t.co/0vScfU8gIX ...

WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company’s Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company’s leadership bench and CEO Steve ...

TORONTO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced that the Company will participate in the following three events during September and October, 2025: September 8-9 – The H.C. Wainwright 27th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York CitySeptember 16-17 – The iAccess Alpha Virtual Best Ideas Fall Investment ConferenceOctober 9 – The 2025 Cantech Letter Investment Confe ...

In a stock market obsessed with AI, Amazon is losing ground https://t.co/ke9BaHP9OJ ...

🚀 Week in AI: Agents Outperform as Sector SlipsBTC cools; dominance <60%; Altseason Index hits 44! Agents pop as WIRE goes ~6,250% on volume! @NEARProtocol pushes user-owned AI! @AlmanakAI raises $8.45M; @TheUpsiderAI cracks Top-10!Let’s unpack what went down this week in AI. 🧵1/6 ...

This Startup Built A Hospital In India To Test Its AI Software https://t.co/fHW7APW4ff https://t.co/oHz2IG99Ne ...

♪ DANI: IT’S 5:00 A. M. IN NEW YORK CITY.GOOD MORNING, I’M DANI BURGER WITH YOUR "BLOOMBERG BRIEF." MORE TALKS. PRESIDENT TRUMP CALLS FOR A MEETING BETWEEN PRESIDENT PUTIN AND ZELENSKIY AND A TRILATERAL WITH HIMSELF. THE BIG INTEL BET.THE TRUMP ADMINISTRATION WEIGHS A 10% STAKE. SOFTBANK BUYS A SURPRISE $2 BILLION WORTH OF SHARES. PLAYING FOR TIME, STOCKS GO NOWHERE FAST AHEAD OF ALL TIME HIGHS AND RETAIL EARNINGS AND JACKSON HOLE.WE’RE STILL GOING NOWHERE THIS MORNING. THE S&P ENTERED DOWN 0.01%. WE’RE SO ...

The AI Hiring Bonanza Is Making Startups Rethink Equity Payouts https://t.co/UmLz2HRwvH ...

Core Viewpoint - Hemostemix Inc. is positioning itself as the world's first AI-driven autologous stem cell therapy company, focusing on enhancing patient care and operational efficiency through artificial intelligence [2][3]. Patient Care Innovations - The company is implementing HIPAA-compliant precision medicine diagnostics that unify various patient data into a single AI-powered analysis, improving the understanding of patient health journeys [4]. - Acurist.AI is being utilized for early cognitive decline screening, allowing for baseline assessments to monitor memory changes before and after treatment with VesCell™ (ACP-01) [5]. - AI-powered patient engagement tools, including personalized chatbot support, are enhancing patient access and satisfaction during treatment and recovery [5]. - AI-driven insights are assisting healthcare providers in tailoring post-therapy plans to help patients maintain healthier habits [6]. Clinical & Scientific Advancement - AI tools are being used to accelerate research by analyzing patient data to predict treatment responses and refine trial designs for VesCell™ (ACP-01) [7]. - Predictive analytics will model therapy success rates based on co-morbidities, lifestyle patterns, and epigenetic markers [7]. - Intelligent agents are streamlining patient recruitment for clinical trials by rapidly screening profiles against trial criteria [8]. Operational Efficiency - Automated administrative workflows, integrated with HubSpot, are reducing overhead costs by up to 20% through efficient management of scheduling, billing, and follow-ups [9]. - AI is optimizing resource allocation by dynamically adjusting staffing and supply chains based on therapy demand [9]. - A unified data ecosystem is being established to ensure seamless, HIPAA-compliant access to clinical trial data and outcome metrics [9]. Compliance & Security - Real-time AI monitoring is being implemented to detect risks and enforce data protection protocols, safeguarding sensitive health information [10]. Company Background - Hemostemix, founded in 2003, specializes in autologous stem cell therapy and has developed the patented VesCell™ (ACP-01) therapy, which has shown promising results in clinical studies for various cardiovascular conditions [12]. - The company has completed seven clinical studies involving 318 subjects, with significant findings published in peer-reviewed journals, including a reported 0% mortality rate in a specific patient population over a follow-up period of up to 4.5 years [12].

RT BSCN (@BSCNews)🚨 @INJECTIVE BRINGS AI INTO DEFINvidia’s most in-demand chip, the H100, is now onchain. Compute costs = a new market to trade 👇https://t.co/BsCiOEtAxG ...